Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

States, U.S. Government Join Caremark "Whistleblower" Lawsuit Over Medicaid Claims

This article was originally published in The Pink Sheet Daily

Executive Summary

The qui tam suit alleges Caremark allowed Medicaid to pay for drugs for patients dually insured by Caremark's health plans and Medicaid, the Texas Attorney General's office says. Four states and the federal government have intervened. Caremark says the lawsuit seeks to impose payment obligations not required by law.

You may also be interested in...



U.S. Attorney Declines To Intervene In Caremark Qui Tam Suit

Illinois U.S. Attorney Patrick Fitzgerald joins colleagues from Florida and California in declining to intervene in qui tam suits against Caremark.

U.S. Attorney Declines To Intervene In Caremark Qui Tam Suit

Illinois U.S. Attorney Patrick Fitzgerald joins colleagues from Florida and California in declining to intervene in qui tam suits against Caremark.

Medco Settlement Will Become PBM "Gold Standard," Prosecutors Say

Prosecutors hope that other PBMs will adopt codes of conduct based on Medco's settlement with 20 state attorneys general over unfair trade practices. Medco will pay $29.3 mil. to settle state claims, but has not yet resolved federal damages.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS062312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel